SMC Update - April 2018
The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Ciprofloxacin ear drops (Cetraxal®) has been accepted for restricted use in the treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane, caused by ciprofloxacin susceptible microorganisms. The restriction limits use to when off-label or unlicensed ciprofloxacin formulations would otherwise be used.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
| « CKS Updates - March 2018 | Zafirlukast discontinued » |
Leave a Comment